Text Size

Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00461123
First received: April 16, 2007
Last updated: August 6, 2012
Last verified: August 2012
History of Changes
Results First Received: September 29, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Prostatic Hypertrophy, Benign
Interventions: Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment started on 19 March 2007 and the last study visit occurred on 02 June 2008. The study was conducted at one center, a university clinic in Germany.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Number of subjects enrolled, randomized and exposed to at least one dose (safety population): 50. Number of subjects who had undergone surgery, whose type of surgery (Greenlight(TM) laser-ablation) had not changed, energy consumption during surgery reported and who had taken the second dose on the day of surgery (intent-to-treat population): 44

Reporting Groups
  Description
Vardenafil (Levitra, BAY38-9456) One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before GreenlightTM laser ablation of prostate commences.
Placebo One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before GreenlightTM laser ablation of prostate commences

Participant Flow:   Overall Study
    Vardenafil (Levitra, BAY38-9456)     Placebo  
STARTED     25     25  
COMPLETED     19     19  
NOT COMPLETED     6     6  
Adverse Event                 1                 0  
Lost to Follow-up                 1                 1  
Protocol Violation                 3                 2  
Withdrawal by Subject                 1                 3  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Vardenafil (Levitra, BAY38-9456) One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before GreenlightTM laser ablation of prostate commences.
Placebo One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before GreenlightTM laser ablation of prostate commences
Total Total of all reporting groups

Baseline Measures
    Vardenafil (Levitra, BAY38-9456)     Placebo     Total  
Number of Participants  
[units: participants]
 		  25     25     50  
Age  
[units: years]
Mean ± Standard Deviation 		  65.8  ± 7.5     65.9  ± 7.9     65.9  ± 7.6  
Gender  
[units: participants]
 		     
Female     0     0     0  
Male     25     25     50  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Baseline-adjusted Least Squared (LS) Means of Peak Urinary Flow (Qmax) at 3 Months After Surgery or Last Observation Carried Forward (LOCF)   [ Time Frame: baseline and up to 3 months after surgery ]
  Show Outcome Measure 1

2.  Secondary:   Baseline-adjusted Least Squared (LS) Means of International Prostate Symptom Score (IPSS) Total Score at 3 Months After Surgery or Last Observation Carried Forward (LOCF)   [ Time Frame: baseline and up to 3 months after surgery ]
  Show Outcome Measure 2

3.  Secondary:   Baseline-adjusted Least Squared (LS) Means of Post-void Residual (PVR) Volume at 3 Months After Surgery or Last Observation Carried Forward (LOCF)   [ Time Frame: baseline and up to 3 months after surgery ]
  Show Outcome Measure 3

4.  Secondary:   Baseline-adjusted Least Squared (LS) Means of the Number of Urinary Incontinence Episodes Per Week at 3 Months After Surgery or Last Observation Carried Forward (LOCF)   [ Time Frame: baseline and up to 3 months after surgery ]
  Show Outcome Measure 4

5.  Secondary:   Duration of Surgery   [ Time Frame: on the day of surgery, without any further allowable time window ]
  Show Outcome Measure 5


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Therapeutic Area Head
Organization: BAYER
e-mail: clinical-trials-contact@bayerhealthcare.com


No publications provided


Responsible Party: Therapeutic Area Head, Bayer Healthcare AG
ClinicalTrials.gov Identifier: NCT00461123     History of Changes
Other Study ID Numbers: 12496, 2006-004633-15
Study First Received: April 16, 2007
Results First Received: September 29, 2009
Last Updated: August 6, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices